TARRYTOWN, N.Y. – U.S. Rep. Nita M. Lowey, (D-Westchester/Rockland), is applauding the $38 million agreement between Tarrytown-based Regeneron Pharmaceuticals Inc. and the Biomedical Advanced Research and Development Authority (BARDA) to develop, test and manufacture a therapy for the treatment of Ebola virus.
Lowey has fought to increase federal investments in BARDA, enabling the development of life-saving treatments.
“The recent Ebola outbreak claimed the lives of nearly 5,000 people,” said Lowey. “I’m proud that scientists and staff at Regeneron will be at the forefront of saving lives and preventing a future outbreak. One of my top priorities in Congress has been increasing funding for biomedical research and development, and as the highest-ranking Democrat on the House committee responsible for providing the funding, I have fought to increase the federal investment in BARDA. I will continue working hard in Congress to protect investments that benefit local companies contributing to the health and safety of the United States.”
Lowey, as ranking mmber of the House Appropriations Committee, successfully fought to prevent a cutoff of BARDA funding and secure $413.5 million in annual appropriations in fiscal year 2014. With Lowey’s assistance, federal investments in BARDA totaled $473 million in fiscal year 2015, and she is fighting to continue to increase investments in biomedical research.
BARDA, an agency within the U.S. Department of Health and Human Services, announced the agreement with Regeneron to develop, test and manufacture a monoclonal antibody therapy for the treatment of Ebola virus infection. BARDA will provide up to a total of $38 million over the next 23 months to support development as well as manufacturing of the experimental monoclonal antibody therapeutic drug for use in studies.
In addition, since she joined the subcommittee that funds medical research, Lowey fought successfully to nearly triple funding to National Institutes of Health.
Click here to sign up for Daily Voice's free daily emails and news alerts.